Stock Taper 
Journey Medical Corporation develops and commercializes dermatology pharmaceuticals in the U.S., including treatments for hyperhidrosis, acne, and fungal conditions, with a portfolio of branded and generic products.
EMROSI™, FDA-approved in November 2024, is a prescription oral medication for adult rosacea inflammatory lesions and a key growth driver for Journey Medical’s innovative dermatology portfolio.
The single most notable event for Journey Medical Corporation in 2025 was the U.S. commercial launch of its key growth driver, Emrosi™ (minocycline hydrochloride), for the treatment of inflammatory lesions in adults with rosacea. This launch, which began in April, positioned the company to compete with the current standard of care after Phase 3 trials showed superior efficacy. The event was the primary driver of a significant revenue increase and positive analyst attention throughout the year.
In 2025, Journey Medical Corporation executed a major strategic shift by launching its flagship product, Emrosi™ (minocycline hydrochloride modified-release capsules, 40 mg), a new oral treatment for rosacea. This launch represents the company's first self-developed drug to go through the full FDA regulatory process and commercialization, marking a significant evolution from its prior focus on acquiring and marketing existing products. The initial success of Emrosi™ is already reshaping the company's financial performance and is positioned as the primary growth driver for its future.
Journey Medical (NASDAQ: DERM - Get Free Report) and Vireo Growth (OTCMKTS:VREOD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Risk and Volatility Journey Medical has a
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
 FENC | $10.42 | COMPARE |
 OBIO | $5.74 | COMPARE |
 OSUR | $3.71 | COMPARE |
 RNAC | $6.66 | COMPARE |
 IVA | $3.30 | COMPARE |
 MDWD | $12.84 | COMPARE |
 HSDT | $2.54 | COMPARE |
 NYXH | $1.45 | COMPARE |
